LUMVOA is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration.
Contraindications
None.
Available Forms
500 mg/10 mL single-dose vial, 50 mg/mL single-dose vial
Mechanism of Action
Veligrotug-vvze's mechanism of action in patients with thyroid eye disease has not been fully characterized. Veligrotug-vvze is a humanized IgG1 monoclonal antibody that binds to IGF-1R and inhibits IGF-1R signaling by blocking ligand-induced receptor autophosphorylation.
Dosage
10 mg/kg every three weeks for a total of 5 infusions Administer LUMVOA by intravenous infusion over 30 to 45 minutes See full prescribing information for dose preparation and administration instructions.
Warnings & Precautions
Infusion Reactions: LUMVOA may cause infusion reactions. Infusion reactions have been reported in approximately 9% of patients treated with LUMVOA.
Inflammatory Bowel Disease: LUMVOA may cause an exacerbation of inflammatory bowel disease (IBD). IBD has been reported in some patients receiving insulin-like growth factor-1 receptor inhibitors without a prior diagnosis of IBD.
Hyperglycemia: Hyperglycemia or increased blood glucose may occur in patients treated with LUMVOA. In clinical trials, 12% of patients, of whom one half had pre-existing diabetes or impaired glucose tolerance, experienced hyperglycemia.
Hearing Impairment Including Hearing Loss: LUMVOA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients' hearing before, during, and after treatment with LUMVOA and consider the benefit-risk of treatment with patients.
Common Side Effects
Most common adverse reactions (incidence of 5% or more) are muscle spasms, headache, hearing impairment, hyperglycemia, fatigue, diarrhea, ear discomfort, infusion-related reaction, nausea, nasopharyngitis, blood creatine phosphokinase increased, dry skin, and hypertension.
Pregnancy & Lactation
Pregnancy: Because inhibiting insulin-like growth factor-1 receptor (IGF-1R) signaling impacts embryonic development and placental development and function, LUMVOA may cause fetal harm when administered to a pregnant woman .
Lactation: There is no information regarding the presence of LUMVOA in human milk, the effects on the breast-fed infant or the effects on milk production.
Pediatric Use
The safety and effectiveness of LUMVOA have not been established in pediatric patients.
GoodRx
Indication
Available Forms
Mechanism of Action
Dosage
Pregnancy & Lactation
Pediatric Use